MedTrace Logo

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

NCT03520478 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 654

Last updated 2021-03-02

No results posted yet for this study

Summary

The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in the treatment of patients with hormone sensitive prostate cancer.

Conditions

Interventions

DRUG

SHR3680

Tablet. Specifications of 80 mg; orally, once a day

DRUG

Bicalutamide

Tablet. Specifications of 50 mg; orally, once a day

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Dingwei Ye, M.D. · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-30
Primary Completion
2023-04-30
Completion
2025-04-30

Countries

  • Bulgaria
  • China
  • Czechia
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03520478 on ClinicalTrials.gov